Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.

Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.